Fig. 2From: Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinibComparison of the PFS curve in ALK-positive advanced NSCLC patients detected by VENTANA IHC or RT-PCR, and treated with crizotinib (8.5 vs. 9.2 months, p = 0.630)Back to article page